ArticleAesthetic plastic surgery2025
Frequency and Characteristics of Delayed-Onset Inflammatory Nodules After Hyaluronic Acid Injections in Japan.
Article in Aesthetic plastic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNo studies in Japan have investigated delayed-onset inflammatory nodules as an adverse event following hyaluronic acid (HA) injections. Our institution, located in a rural area with no nearby aesthetic clinics, allows for comprehensive follow-up of HA-treated patients. This study analyzed complications from 673 cases over 6 years, focusing on delayed-onset inflammatory nodules.
methodsA retrospective review of medical records was conducted for patients treated with AbbVie-Allergan HA products between January 2018 and December 2023. Adverse events were categorized as acute complications or delayed-onset inflammatory nodules. Statistical analysis assessed product type, time to onset, patient history, and treatment approaches.
resultsOne acute allergic reaction and seven cases (1.07%) of delayed-onset inflammatory nodules were identified. Volbella was involved in 4 cases, Volift in 1 case, Voluma in 1 case, and Ultra Plus in 1 case. Statistical analysis revealed a significantly higher incidence with Volbella (p = 0.0484). The average onset was 144 days, with no seasonal pattern. Among affected patients, three had a history of non-HA-related allergies, and one had a preceding infection. Treatments included oral antibiotics (2 cases), oral antihistamines (5 cases), topical steroids (3 cases), hyaluronidase injections (4 cases), oral steroids (2 cases), and surgical intervention (1 case).
conclusionsDelayed-onset inflammatory nodules occurred in approximately 1% of cases, with Volbella showing the highest incidence. Patients with allergies or prior infections may have an increased risk. Comprehensive informed consent should emphasize potential delayed complications to ensure patient understanding. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
Indexed as
Identifiers
40906285What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.